• 18 Aug 20

MaxCyte Inc: Analyst talks expansion of its phase I clinical trial of MCY-M11

MaxCyte Inc: Analyst talks expansion of its phase I clinical trial of MCY-M11

MaxCyte, Inc. | MYE0 | 0 0 0%

    • 117 views

 

Proactive Research analyst Emma Ulker discusses the update this morning from MaxCyte Inc (LON:MXCT) on the expansion of its phase I clinical trial of MCY-M11 - its differentiated lead cell therapy candidate currently in first-in-human studies for advanced solid cancers. Ulker says the move is a natural progression based on promising preliminary data from the study which was presented at the virtual meeting of the American Society of Clinical Oncology (ASCO) in May.

Enjoying this article?

Get a £25 credit by sharing with your friends and colleagues via our Refer a Friend page. Each new subscriber gets a 10% discount and you get a free month off your bill every time.


Don't worry, if you're a Lite-Access/Free user we save all your credits for the day you decide to fully subscribe.


 

Maxcyte (MXCT) - Vox Markets Fund Manager Series: Q&A with Amati Global Investors fund manager, Dr Paul Jourdan

Companies: MaxCyte, Inc.

MaxCyte appoints life-sciences vet as EVP, updates on lead therapy to treat solid tumors

Companies: MaxCyte, Inc.

FTSE 100 opens up in spite of more heavy losses on Wall Street overnight with Melrose Industries top

Companies: MaxCyte, Inc.

MaxCyte (MXCT) presentation at ShareSoc July 2018

Companies: MaxCyte, Inc.

Maxcyte (AIM:MXCT) - Doug Doerfler, CEO Presenting at the Proactive One2One Virtual Forum - Dec 2021

Companies: MaxCyte, Inc.

MaxCyte increases dose level for mesothelioma and ovarian cancer patients in its Phase I trials

Companies: MaxCyte, Inc.

© Research Tree 2026

  • Apple Store
  • Play Store

Research Tree will never share your details with third parties for marketing purposes. Research Tree distributes research documents that have been produced and approved by Financial Conduct Authority (FCA) Authorised & Regulated firms as well as relevant content from non-authorised sources, who are not regulated but the information is in the public domain. For the avoidance of doubt Research Tree is not giving advice, nor has Research Tree validated any of the information.

Research Tree is an Appointed Representative of Sturgeon Ventures which is Authorised and Regulated by the Financial Conduct Authority.

Top